Literature DB >> 17969070

Treatment of alcoholic liver disease.

Christopher Paul Day1.   

Abstract

Severe alcoholic steatohepatitis (ASH) is the major complication of advanced alcoholic liver disease (ALD) and has a high mortality even when treated with corticosteroids. Despite the importance of reactive oxygen species in the pathophysiology of ALD and ASH, antioxidants provide no benefit in the treatment of patients with ASH. Proinflammatory cytokines are important in the pathophysiology of ALD and might mediate most of the inflammatory aspects of these disorders. New treatment modalities in ASH might involve antagonism of proinflammatory cytokines such as tumor necrosis factor (TNF) by specific antibodies or other TNF-interfering treatment strategies. Propylthiouracil and S-adenosyl methionine may be beneficial to patients with alcoholic cirrhosis, but both require further randomized, controlled trials before their use can be recommended.Liver transplantation is an effective therapy for patients with advanced alcoholic cirrhosis who have not recovered after a period of abstinence.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17969070     DOI: 10.1002/lt.21336

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  14 in total

Review 1.  Prevention of hepatocellular carcinoma: potential targets, experimental models, and clinical challenges.

Authors:  Yujin Hoshida; Bryan C Fuchs; Kenneth K Tanabe
Journal:  Curr Cancer Drug Targets       Date:  2012-11-01       Impact factor: 3.428

Review 2.  Chronic liver inflammation: clinical implications beyond alcoholic liver disease.

Authors:  Byoung-Jin Park; Yong-Jae Lee; Hye-Ree Lee
Journal:  World J Gastroenterol       Date:  2014-03-07       Impact factor: 5.742

Review 3.  Treatment of Alcohol Use Disorder in Patients with Alcoholic Liver Disease.

Authors:  Lorenzo Leggio; Mary R Lee
Journal:  Am J Med       Date:  2016-10-29       Impact factor: 4.965

4.  Treatment of alcoholic liver disease.

Authors:  Thomas H Frazier; Abigail M Stocker; Nicole A Kershner; Luis S Marsano; Craig J McClain
Journal:  Therap Adv Gastroenterol       Date:  2011-01       Impact factor: 4.409

Review 5.  Ethanol and liver: recent insights into the mechanisms of ethanol-induced fatty liver.

Authors:  Jinyao Liu
Journal:  World J Gastroenterol       Date:  2014-10-28       Impact factor: 5.742

Review 6.  Inflammation in alcoholic liver disease.

Authors:  H Joe Wang; Bin Gao; Samir Zakhari; Laura E Nagy
Journal:  Annu Rev Nutr       Date:  2012-04-18       Impact factor: 11.848

Review 7.  The immunopathogenesis of alcoholic and nonalcoholic steatohepatitis: two triggers for one disease?

Authors:  Luca Valenti; Anna Ludovica Fracanzani; Silvia Fargion
Journal:  Semin Immunopathol       Date:  2009-05-14       Impact factor: 9.623

8.  PPAR/RXR Regulation of Fatty Acid Metabolism and Fatty Acid omega-Hydroxylase (CYP4) Isozymes: Implications for Prevention of Lipotoxicity in Fatty Liver Disease.

Authors:  James P Hardwick; Douglas Osei-Hyiaman; Homer Wiland; Mohamed A Abdelmegeed; Byoung-Joon Song
Journal:  PPAR Res       Date:  2010-03-16       Impact factor: 4.964

Review 9.  Strategies to rescue steatotic livers before transplantation in clinical and experimental studies.

Authors:  Qiang Liu; Maria-Louisa Izamis; Hongzhi Xu; Tim Berendsen; Martin Yarmush; Korkut Uygun
Journal:  World J Gastroenterol       Date:  2013-08-07       Impact factor: 5.742

Review 10.  Risk factors and prevention of hepatocellular carcinoma in the era of precision medicine.

Authors:  Naoto Fujiwara; Scott L Friedman; Nicolas Goossens; Yujin Hoshida
Journal:  J Hepatol       Date:  2017-10-06       Impact factor: 30.083

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.